Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)

Condition(s) studied

Investigational drug(s) / intervention(s)

PCSK9 inhibitor: the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.

Statin: the control group will receive standard statin therapy.

Study summary

This is a multi-center, randomized controlled study to investigate whether early offering PCSK9 inhibitor can protect against negative inflammatory response and organ dysfunction after coronary artery bypass grafting (CABG). Subjects with myocardial ischaemic syndromes (MIS) will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy, while the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later. Six month after CABG, CRP will be used to evaluate inflammation, and echocardiography and coronary CTA will be used to evaluate cardiovascular function.

Eligibility

Primary outcome measure(s)

• Major Adverse Cardiovascular and Cerebrovascular Events — 6 months after surgery
  Major Adverse Cardiovascular and Cerebrovascular Events include cardiac death, reinfarction, emergency coronary revascularization and stroke

Trial sites (2)

More Nanjing Medical University trials in China

Other trials for the same condition